Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx Limited (NYSE AMERICAN: VNRX) presented new data on its Nu.Q® NETs test at the ISTH Congress on July 13, 2022. The research, conducted with the University of Namur and QUALIblood, explores NETosis biomarkers in sepsis and COVID-19. Key findings include a correlation between Nu.Q® NET levels and the SOFA score, potentially aiding in patient diagnosis. Volition's Chief Scientific Officer emphasized the significance of this congress for building collaborations and advancing clinical applications of Nu.Q® tests in Europe.
VolitionRx Limited (VNRX) has announced the CE marking of its Nu.Q® NETs test for the detection and evaluation of NETosis, allowing clinical use in over 27 European countries. This test can detect NETosis through routine blood tests, offering significant commercial potential with a Total Addressable Market of approximately $6.5 billion for sepsis in Europe. The company expects to start commercialization in the first half of 2023. The test aims to support physicians in managing diseases associated with NETosis, including sepsis and COVID-19.
VolitionRx Limited (VNRX) reported financial results for Q1 2022, highlighting a net loss of $7.7 million compared to $6.1 million in Q1 2021. Cash reserves increased to $23.7 million, boosted by a $10 million milestone payment from Heska Corporation following a major licensing agreement for the Nu.Q® Vet Cancer Screening Test. The company is also expanding its operations with new hires and recent product launches in Singapore. Upcoming milestones include further licensing agreements, sales of test components, and clinical studies.
VolitionRx Limited (NYSE AMERICAN: VNRX) will hold a conference call on May 12, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and business updates. The call will feature CEO Cameron Reynolds and other executives. Additionally, a Capital Markets Day is scheduled for May 13, 2022, at 10:00 a.m. ET at the New York Stock Exchange. These events aim to provide insight into recent developments and future milestones within the company.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a hybrid Capital Markets Day on May 13, 2022, at 10 a.m. Eastern Time. The event, held at Siebert Hall, NYSE, will feature the executive team providing strategic updates and discussing key growth drivers. Topics include veterinary market opportunities, clinical results, and financial metrics. Attendees can register for virtual participation. Presentations will be available on the company’s website, with a replay offered post-event.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the launch of its Nu.Q® Vet Cancer Test in Asia via distributor SAGE Healthcare on April 25, 2022. Following their appointment in December 2021, SAGE has commenced marketing the test, which aims to facilitate early cancer detection in pets. CEO Dr. Jasmine Kway emphasized the growing pet ownership in Asia, presenting a significant market opportunity for the test. SAGE plans to expand the product's availability to other Asian markets.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Sharon Ballesteros as the U.S. Head of Quality and Development Process, effective April 4, 2022. Ballesteros brings over 20 years of experience from her previous roles at Siemens Health Diagnostics and GRAIL. This move supports Volition's expansion efforts in California, including a new 6,000 ft lab in Carlsbad. The company aims to enhance its regulatory processes to commercialize its Nu.Q® diagnostic products for various diseases. A warrant for 54,000 shares at $3.05 per share was granted to Ballesteros as part of her appointment.
VolitionRx Limited (NYSE AMERICAN: VNRX) provided a business update on March 30, 2022, announcing a global licensing deal with Heska Corporation for the Nu.Q® Vet Cancer Screening Test. This deal includes a $10 million upfront payment and potential milestone payments of up to $18 million. Volition reported a net loss of $27 million for 2021, largely due to non-cash items and increased staffing costs, with cash reserves totaling $20.6 million. The company continues to advance its product development and has a total addressable market estimated at $70 billion.
VolitionRx Limited (NYSE AMERICAN: VNRX) has entered an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) to market its Nu.Q® Vet Cancer Screening Test for companion animals. This deal includes a $10 million upfront payment and up to $18 million for milestone achievements. The test aims to enhance early cancer detection in dogs and cats, targeting a global market estimated at $11 billion. Administrating this test will be facilitated through Heska's proprietary analyzers, making it accessible and affordable for veterinarians.
Heska Corporation (NASDAQ: HSKA) has entered an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) to commercialize the Nu.Q® Vet Cancer Screening Test for companion animals. This test aims to provide veterinarians with the ability to screen pets for cancer at the point of care. With an estimated $11 billion market for canine and feline cancer screening, this innovative solution is expected to greatly enhance early detection and treatment for pets, benefiting both healthcare outcomes and pet owners.
FAQ
What is the current stock price of VolitionRX (VNRX)?
What is the market cap of VolitionRX (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
